Congress questions celebrity endorsements, FDA oversight of DTC drug ads
The campaign against drug TV advertising and marketing seems to be accelerating in Washington and around the country. The latest salvo comes from leaders of the House Energy & Commerce Committee who want information from pharmaceutical companies and the Food and Drug Administration about questionable marketing campaigns.
The campaign against drug TV advertising and marketing seems to be accelerating in Washington and around the country. The latest salvo comes from leaders of the House Energy & Commerce Committee who want information from pharmaceutical companies and the Food and Drug Administration about questionable marketing campaigns.
E&C Chairman John Dingell and Oversight Subcommittee Chairman Bart Stupak, both Michigan Democrats, are questioning the use of celebrity spokesman Dr. Robert Jarvik in Pfizer commercials for Lipitor (atorvastatin). The legislators consider the ads misleading because Jarvik is not a heart specialist and didn’t perform the energetic rowing shown in TV commercials featuring his comments.
Celebrity endorsements are problematic for any DTC advertising, according to the investigators. However, they consider it particularly troubling to use stunt doubles in ads designed to emphasize a medicine’s powerful effectiveness.
The crack-down on Lipitor ads by the House committee follows their investigation into ads for Vytorin promoting the drugs effectiveness, which subsequently came into question. The committee demanded that FDA provide it with all agency records relating to print, broadcast and internet advertising for Vytorin, which brought in boxes of documents and disks. In addition, co-marketers Merck and Schering-Plough halted consumer advertising of Vytorin.
Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
